epilepsy
EpilepsyGTx raises $33m for focal refractory epilepsy gene therapy
December 10, 2025Research and Development EpilepsyGTx, Neurology, epilepsy
EpilepsyGTx, a biotechnology company researching and developing gene therapies for the treatment of refractory epilepsy, has announced $33m raised in …
UCB presents positive results for fenfluramine in CDKL5 deficiency disorder
December 8, 2025Research and Development Neurology, UCB, epilepsy
UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can significantly reduce the frequency of …
Rare and severe epilepsies – current treatments and advance therapeutics
August 29, 2025Medical Communications, Research and Development Neurology, UCB, epilepsy, epilepsy treatment, rare epilepsies
The current forms of immunotherapy, how T cell therapy works and what the future holds
Epilepsy Research Institute opens 2025-26 grant round with new awards
August 21, 2025Medical Communications, Research and Development Neurology, epilepsy, funding programme, medical research
The Epilepsy Research Institute has opened its 2025-26 Grant Round, offering a wide range of funding opportunities designed to support …
Five Facts about epilepsy
August 21, 2025Medical Communications Five Facts, Neurology, epilepsy, neurological condition, seizures
1 Epilepsy occurs when the normal electrical activity in the brain changes. For many, the cause is unclear, but genes …
Biogen and Stoke report positive results for Dravet syndrome drug
July 17, 2025Research and Development Biogen, Dravet Syndrome, Neurology, Stoke Therapeutics, epilepsy, rare diseases
Biogen and Stoke Therapeutics have shared encouraging new data for their experimental treatment, zorevunersen, which is being developed for Dravet …
Angelini Pharma and JCR Pharmaceuticals partner to develop new epilepsy therapies
May 12, 2023Sales and Marketing Angelini Pharma, JCR Pharmaceuticals, Neurology, epilepsy
Angelini Pharma and JCR Pharmaceuticals have announced that they have entered into an exclusive global development and commercialisation agreement for …
Epilepsy drug receives MHRA marketing authorisation
June 17, 2021MHRA, epilepsy, marketing authorisation
The MHRA has granted marketing authorisation (MA) for Ontozry (cenobamate) for the treatment of focal-onset seizures in adult patients with …
Accure Therapeutics’ drug candidate can slow epilepsy progression, study shows
February 10, 2021Research and Development epilepsy
Accure Therapeutics, an R&D pharmaceutical company in the central nervous system (CNS) field, has announced the publication of a pivotal …
EMA recommends Arvelle’s seizure drug cenobamate
February 2, 2021Manufacturing and Production Arvelle Therapeutics, epilepsy
The EMA has recommended the approval of Arvelle Therapeutics’ cenobamate for the adjunctive treatment of focal onset seizures with or …
NHS guidelines on prescription cannabis to be challenged in court
August 18, 2020Manufacturing and Production, Research and Development CBD, cannabis, epilepsy
The cannabis guidelines followed by the NHS are set to be challenged in court by the parents of a three-year-old …
EMA gives market authorisation application to epilepsy treatment from Arvelle Therapeutics
March 30, 2020Sales and Marketing EMA, EMA approvals, approvals, epilepsy
The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for a cenobamate adjunctive treatment of focal-onset seizures …
Idorsia reveals it is working with Neurocrine on new epilepsy drug deal
January 10, 2020Medical Communications FDA, Idorsia, Neurocrine, drugs, epilepsy, pharma
Idorsia revealed its 2019 deal for its investigational epilepsy medicine was with Neurocrine Biosciences, and it is potentially worth more …
NHS to fast track cannabis-based treatment for epilepsy
December 23, 2019Sales and Marketing CBD, CBD Oil, cannabis, drug treatment, epilepsy, thc
The NHS has fast-tracked the drug Epidyolex, a cannabidiol (CBD), to be available for epilepsy treatment through the NHS in …
China approves Eisai’s Fycompa for partial onset epileptic seizures
October 16, 2019Research and Development, Sales and Marketing China, Eisai, Fycompa, epilepsy, pharma
Tokyo-headquartered firm Eisai has announced that its antiepileptic drug (AED) Fycompa (perampanel) has received approval from China’s National Medical Products …
